Abilify MyCite

By Dave Muoio June 6, 2018
Stakeholders across healthcare are beginning to weigh the benefits and challenges digital therapeutics could bring to their businesses, and pharma is no exception. During an afternoon roundtable session held Wednesday at BIO 2018 in Boston, a panel of digital medicine and pharmaceutical representatives discussed the impact that these novel medicines has had, and could have, on drugmakers,...
By Dave Muoio March 8, 2018
It’s still the early days, but the FDA’s approval of Proteus Digital Health and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare. The first approval of drug delivery via a sensor-equipped pill sparked debates over the tradeoff of privacy for medication adherence, and whether these types of technologies would find a role in future healthcare....
By Jonah Comstock November 17, 2017
Correction: An earlier version of this article was unclear about differences between Abilify MyCite and the Proteus Digital Medicine Platform.  Earlier this week, Proteus Digital Health and Otsuka Pharmaceuticals announced that Abilify MyCite, a new, sensor-enabled version of Otsuka’s drug for schizophrenia, had received FDA approval for mental health conditions including schizophrenia and...